Class Action Lawsuit Filed Against Pacira Biosciences, Inc.: What Does This Mean for Investors and the World?
On February 26, 2025, Pomerantz LLP, a leading securities law firm, announced the filing of a class action lawsuit against Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ:PCRX) in the United States District Court for the Southern District of New York. The complaint alleges that Pacira and certain of its executives violated the Securities Exchange Act of 1934.
Impact on Investors
The class action lawsuit alleges that Pacira and its executives made false and misleading statements regarding the Company’s financial results and business prospects. Specifically, the complaint alleges that Pacira failed to disclose that certain of its products were experiencing declining sales, and that the Company’s revenue growth was decelerating. These allegations, if proven, could result in significant damages for investors.
Impact on the World
The impact of this class action lawsuit on the world at large may depend on the outcome of the litigation. If the allegations are proven, it could lead to increased scrutiny of Pacira’s business practices and potential regulatory action. Additionally, it could lead to a decline in investor confidence in the biotech industry as a whole, particularly in companies with similar business models or product portfolios.
Details of the Lawsuit
According to the complaint, Pacira and its executives made false and misleading statements and failed to disclose material information to investors. The complaint alleges that Pacira failed to disclose that its Exparel product, a long-acting local anesthetic, was experiencing declining sales due to increased competition and pricing pressures. The complaint also alleges that Pacira failed to disclose that its revenue growth was decelerating, and that the Company’s financial statements contained material misstatements and omissions.
The complaint seeks to recover damages on behalf of all persons or entities who purchased or otherwise acquired Pacira securities between March 5, 2021 and February 25, 2025, inclusive (the “Class Period”).
What Should Investors Do?
If you are a Pacira investor and believe that you have suffered a loss as a result of Pacira’s actions, you may be eligible to recover your losses. You may, no later than May 2, 2025, request that the Court appoint you as lead plaintiff of the proposed class. To be a lead plaintiff, you must meet certain requirements set forth in the Securities Exchange Act of 1934. To receive more information, please contact Danielle Peyton at [email protected] or 646-581-9980, toll-free, Ext. 7925.
Conclusion
The filing of a class action lawsuit against Pacira Biosciences, Inc. is a significant development for investors in the Company’s securities. If the allegations are proven, it could result in significant damages for investors and increased scrutiny of Pacira’s business practices. Investors who believe they have suffered losses as a result of Pacira’s actions should consider contacting Pomerantz LLP for more information.
- Pacira Biosciences, Inc. (NASDAQ:PCRX) is the subject of a class action lawsuit alleging securities law violations.
- The lawsuit alleges that Pacira and its executives made false and misleading statements regarding the Company’s financial results and business prospects.
- The impact on investors could be significant if the allegations are proven.
- The impact on the world may depend on the outcome of the litigation.
- Investors who believe they have suffered losses as a result of Pacira’s actions should consider contacting Pomerantz LLP for more information.
